Tonix Pharmaceuticals Holding Corp. (TNXP)
↓ Download CSV- Sector Manufacturing
- Incorporated NV
- Fiscal year ends Dec 31
In fiscal 2025, Tonix Pharmaceuticals Holding Corp. reported revenue of $13.11M, up 29.8% from the prior year. The company ran a net loss, with a net margin of -946.2%. It held $277.17M in total assets against $32.02M in total liabilities.
Key ratios (FY2025)
-959.1%
Operating margin
-946.2%
Net margin
-50.6%
Return on equity
+29.8%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.11M | $10.09M | $7.77M | — | — | — | — | — | — | — |
| Cost of Revenue | $6.64M | $7.76M | $4.74M | — | — | — | — | — | — | — |
| Operating Income | -$125.70M | -$136.70M | -$118.38M | -$112.09M | -$92.31M | -$50.51M | -$28.83M | -$26.32M | -$21.29M | -$38.97M |
| Net Income | -$124.02M | -$130.04M | -$116.66M | -$110.22M | -$92.29M | -$50.46M | -$28.62M | -$26.09M | -$21.12M | -$38.84M |
| EPS (Diluted) | $-14.57 | $-176.60 | $-14720.25 | $-20.01 | $-8.10 | — | — | — | — | — |
| Total Assets | $277.17M | $162.89M | $154.46M | $225.69M | $240.90M | $98.18M | $14.56M | $26.32M | $26.75M | $27.51M |
| Total Liabilities | $32.02M | $23.33M | $48.93M | $18.51M | $22.18M | $10.54M | $5.14M | $2.65M | $2.14M | $2.15M |
| Shareholders' Equity | $245.15M | $139.56M | $105.53M | $207.18M | $218.72M | $87.65M | $9.42M | $23.66M | $24.62M | $25.36M |
| Cash & Equivalents | $207.64M | $98.78M | $24.95M | $120.23M | $178.66M | $77.07M | $11.25M | $25.03M | $25.50M | $18.94M |
| Operating Cash Flow | -$99.84M | -$60.92M | -$102.00M | -$98.05M | -$75.56M | -$48.57M | -$26.68M | -$23.97M | -$19.13M | -$37.31M |
| Capital Expenditures | $3.37M | $120.0K | $7.89M | $48.15M | $35.31M | $8.56M | $17.0K | $6.0K | $5.0K | $66.0K |
| Shares Outstanding | 12.79M | 4.39M | 20.9K | 12.37M | 15.64M | 206.01M | 8.53M | 328.7K | 785.9K | 3.92M |